Cerivastatin sodium (BioDeep_00000777712)

   


代谢物信息卡片


Cerivastatin sodium

化学式: C26H33FNNaO5 (481.2240340000001)
中文名称: 头孢伐他汀钠
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC(C)C1=C(C(=C(C(=N1)C(C)C)COC)C2=CC=C(C=C2)F)C=CC(CC(CC(=O)[O-])O)O.[Na+]
InChI: /q

描述信息

D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents
D004791 - Enzyme Inhibitors > D019161 - Hydroxymethylglutaryl-CoA Reductase Inhibitors
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent
C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor
D009676 - Noxae > D000963 - Antimetabolites
Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect[1][2].

同义名列表

2 个代谢物同义名

Cerivastatin sodium; Cerivastatin (sodium)



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Sarah A Long, Shan Huang, Anusha Kambala, Ling Ren, Jennifer Wilson, Michael Goetz, Xiaojiang Hao, Xiaosheng Yang, Ekaterina I Goncharova, Libin Jia, Amy LeBlanc, Chand Khanna, Curtis J Henrich, John A Beutler. Identification of potential modulators of osteosarcoma metastasis by high-throughput cellular screening of natural products. Chemical biology & drug design. 2021 01; 97(1):77-86. doi: 10.1111/cbdd.13762. [PMID: 32666679]
  • Stephen P Adams, Nicholas Tiellet, Nima Alaeiilkhchi, James M Wright. Cerivastatin for lowering lipids. The Cochrane database of systematic reviews. 2020 01; 1(?):CD012501. doi: 10.1002/14651858.cd012501.pub2. [PMID: 31981471]
  • Yan Wang, Jun Zhang, Yanrong Ma, Xiangxin Song, Suli Li, Xianqin Zhan, Lan Wu. Different lipid profiles, insulin sensitivity, and insulin resistance among Han, Uygur, and Kazak men with normal glucose tolerance in Xinjiang, China. Lipids in health and disease. 2018 Sep; 17(1):209. doi: 10.1186/s12944-018-0863-9. [PMID: 30193578]
  • Akiko Matsubara, Shingo Oda, Sho Akai, Koichi Tsuneyama, Tsuyoshi Yokoi. Establishment of a drug-induced rhabdomyolysis mouse model by co-administration of ciprofloxacin and atorvastatin. Toxicology letters. 2018 Jul; 291(?):184-193. doi: 10.1016/j.toxlet.2018.04.016. [PMID: 29679711]
  • Hisakuni Obayashi, Naoko Kobayashi, Yoshikazu Nezu, Takashi Yamoto, Mitsuyuki Shirai, Fumitoshi Asai. Plasma 2-hydroxyglutarate, a promising prognostic biomarker candidate for skeletal muscle injury in Fischer 344 rats. The Journal of toxicological sciences. 2018; 43(10):601-610. doi: 10.2131/jts.43.601. [PMID: 30298848]
  • Hisakuni Obayashi, Naoko Kobayashi, Yoshikazu Nezu, Takashi Yamoto, Mitsuyuki Shirai, Fumitoshi Asai. Plasma 2-hydroxyglutarate and hexanoylcarnitine levels are potential biomarkers for skeletal muscle toxicity in male Fischer 344 rats. The Journal of toxicological sciences. 2017; 42(4):385-396. doi: 10.2131/jts.42.385. [PMID: 28717097]
  • Rowena H Gee, Jenny N Spinks, Jason M Malia, Jonathan D Johnston, Nick J Plant, Kathryn E Plant. Inhibition of prenyltransferase activity by statins in both liver and muscle cell lines is not causative of cytotoxicity. Toxicology. 2015 Mar; 329(?):40-8. doi: 10.1016/j.tox.2015.01.005. [PMID: 25578243]
  • K M Burgazli, K L Bui, M Mericliler, A T Albayrak, M Parahuleva, A Erdogan. The effects of different types of statins on proliferation and migration of HGF-induced Human Umbilical Vein Endothelial Cells (HUVECs). European review for medical and pharmacological sciences. 2013 Nov; 17(21):2874-83. doi: . [PMID: 24254555]
  • Mark J Cziraky, Vincent J Willey, James M McKenney, Siddhesh A Kamat, Maxine D Fisher, John R Guyton, Terry A Jacobson, Michael H Davidson. Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. Journal of clinical lipidology. 2013 Mar; 7(2):102-8. doi: 10.1016/j.jacl.2012.06.006. [PMID: 23415428]
  • Alejandro Álvarez-Prats, Octavio Hernández-Perera, Pilar Díaz-Herrera, Álvaro C Ucero, Aránzazu Anabitarte-Prieto, Antonio Losada-Cabrera, Alberto Ortiz, José C Rodríguez-Pérez. Combination therapy with an angiotensin II receptor blocker and an HMG-CoA reductase inhibitor in experimental subtotal nephrectomy. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2012 Jul; 27(7):2720-33. doi: 10.1093/ndt/gfr671. [PMID: 22302208]
  • Masaki Kobayashi, Kazuhiro Hidaka, Ikumi Chisaki, Natsuko Takahashi, Jiro Ogura, Shirou Itagaki, Takeshi Hirano, Hiroaki Yamaguchi, Ken Iseki. [Effects of acidification and alkalinization agents on statins-induced muscle toxicity]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. 2012; 132(5):609-15. doi: 10.1248/yakushi.132.609. [PMID: 22687697]
  • Hisakuni Obayashi, Yoshikazu Nezu, Hatsue Yokota, Naoki Kiyosawa, Kazuhiko Mori, Naoyuki Maeda, Yoshiro Tani, Sunao Manabe, Atsushi Sanbuissho. Cerivastatin induces type-I fiber-, not type-II fiber-, predominant muscular toxicity in the young male F344 rats. The Journal of toxicological sciences. 2011 Aug; 36(4):445-52. doi: 10.2131/jts.36.445. [PMID: 21804308]
  • Nelly Aranibar, Jeffrey D Vassallo, John Rathmacher, Steve Stryker, Yingru Zhang, Jun Dai, Evan B Janovitz, Don Robertson, Michael Reily, Linda Lowe-Krentz, Lois Lehman-McKeeman. Identification of 1- and 3-methylhistidine as biomarkers of skeletal muscle toxicity by nuclear magnetic resonance-based metabolic profiling. Analytical biochemistry. 2011 Mar; 410(1):84-91. doi: 10.1016/j.ab.2010.11.023. [PMID: 21094120]
  • Jeffrey D Vassallo, Evan B Janovitz, Debra M Wescott, Chris Chadwick, Linda J Lowe-Krentz, Lois D Lehman-McKeeman. Biomarkers of drug-induced skeletal muscle injury in the rat: troponin I and myoglobin. Toxicological sciences : an official journal of the Society of Toxicology. 2009 Oct; 111(2):402-12. doi: 10.1093/toxsci/kfp166. [PMID: 19628585]
  • C Y Vossen, M M Hoffmann, H Hahmann, B Wüsten, D Rothenbacher, H Brenner. Effect of APOE genotype on lipid levels in patients with coronary heart disease during a 3-week inpatient rehabilitation program. Clinical pharmacology and therapeutics. 2008 Aug; 84(2):222-7. doi: 10.1038/clpt.2008.31. [PMID: 18388879]
  • Juyong Wang, Zhenye Xu, Isao Kitajima, Zhongqi Wang. Effects of different statins on endothelial nitric oxide synthase and AKT phosphorylation in endothelial cells. International journal of cardiology. 2008 Jun; 127(1):33-9. doi: 10.1016/j.ijcard.2007.10.034. [PMID: 18201784]
  • Mohammad Z Chaudhry, Jiang Huai Wang, Siobhan Blankson, H Paul Redmond. Statin (cerivastatin) protects mice against sepsis-related death via reduced proinflammatory cytokines and enhanced bacterial clearance. Surgical infections. 2008 Apr; 9(2):183-94. doi: 10.1089/sur.2006.077. [PMID: 18426351]
  • Louise A Donnelly, Colin N A Palmer, Adrian L Whitley, Chim Choy Lang, Alex S F Doney, Andrew D Morris, Peter T Donnan. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. Pharmacogenetics and genomics. 2008 Apr; 18(4):279-87. doi: 10.1097/fpc.0b013e3282f60aad. [PMID: 18334912]
  • Chelsie Estey, Xi Chen, Thomas W Moon. 3-Hydroxy-3-methylglutaryl coenzyme A reductase in rainbow trout: effects of fasting and statin drugs on activities and mRNA transcripts. Comparative biochemistry and physiology. Toxicology & pharmacology : CBP. 2008 Apr; 147(3):386-98. doi: 10.1016/j.cbpc.2008.01.008. [PMID: 18280795]
  • Tomoyuki Nishimoto, Eiichiro Ishikawa, Hisashi Anayama, Hitomi Hamajyo, Hirofumi Nagai, Masao Hirakata, Ryuichi Tozawa. Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs. Toxicology and applied pharmacology. 2007 Aug; 223(1):39-45. doi: 10.1016/j.taap.2007.05.005. [PMID: 17599378]
  • H Scharnagl, T Stojakovic, K Winkler, S Rosinger, W März, B O Boehm. The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. 2007 Jun; 115(6):372-5. doi: 10.1055/s-2007-973830. [PMID: 17701882]
  • F E Cohen-Boulakia, K Tarhzaoui, P E Valensi, R A Lestrade, J P Albertini, A Behar. Effect of cerivastatin on peripheral capillary permeability to albumin and peripheral nerve function in diabetic rats. Diabetes & metabolism. 2007 Jun; 33(3):189-96. doi: 10.1016/j.diabet.2006.11.012. [PMID: 17379559]
  • Faikah Gueler, Joon-Keun Park, Song Rong, Torsten Kirsch, Carsten Lindschau, Wen Zheng, Marlies Elger, Anette Fiebeler, Danilo Fliser, Friedrich C Luft, Hermann Haller. Statins attenuate ischemia-reperfusion injury by inducing heme oxygenase-1 in infiltrating macrophages. The American journal of pathology. 2007 Apr; 170(4):1192-9. doi: 10.2353/ajpath.2007.060782. [PMID: 17392159]
  • Gerd Schmitz, Anna Schmitz-Madry, Peter Ugocsai. Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy. Current opinion in lipidology. 2007 Apr; 18(2):164-73. doi: 10.1097/mol.0b013e3280555083. [PMID: 17353665]
  • Marie-Louise Koepke, Manfred Weber, Eckhard Schulze-Lohoff, Bogdan Beirowski, Stephan Segerer, Oliver Gross. Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2007 Apr; 22(4):1062-9. doi: 10.1093/ndt/gfl810. [PMID: 17287218]
  • Barbara J Meyer, Tone Hammervold, Arild Chr Rustan, Peter R C Howe. Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects. Lipids. 2007 Mar; 42(2):109-15. doi: 10.1007/s11745-006-3014-4. [PMID: 17393216]
  • Atsushi Takagi, Yukio Tsurumi, Naoko Ishizuka, Hisako Omori, Kotaro Arai, Nobuhisa Hagiwara, Hiroshi Kasanuki. Single administration of cerivastatin, an HMG-CoA reductase inhibitor, improves the coronary flow velocity reserve: a transthoracic Doppler echocardiography study. Heart and vessels. 2006 Sep; 21(5):298-301. doi: 10.1007/s00380-006-0905-5. [PMID: 17151817]
  • Masaki Kobayashi, Yukio Otsuka, Shirou Itagaki, Takeshi Hirano, Ken Iseki. Inhibitory effects of statins on human monocarboxylate transporter 4. International journal of pharmaceutics. 2006 Jul; 317(1):19-25. doi: 10.1016/j.ijpharm.2006.02.043. [PMID: 16621368]
  • Masato Eto, Lisa Rathgeb, Francesco Cosentino, Toshiyuki Kozai, Thomas F Lüscher. Statins blunt thrombin-induced down-regulation of endothelial nitric oxide synthase expression in human endothelial cells. Journal of cardiovascular pharmacology. 2006 May; 47(5):663-7. doi: 10.1097/01.fjc.0000211754.54691.f3. [PMID: 16775505]
  • Mark J Cziraky, Vincent J Willey, James M McKenney, Siddhesh A Kamat, Maxine D Fisher, John R Guyton, Terry A Jacobson, Michael H Davidson. Statin safety: an assessment using an administrative claims database. The American journal of cardiology. 2006 Apr; 97(8A):61C-68C. doi: 10.1016/j.amjcard.2005.12.011. [PMID: 16581331]
  • Jennifer L Seachrist, Cho-Ming Loi, Mark G Evans, Kay A Criswell, Charles E Rothwell. Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity. Toxicological sciences : an official journal of the Society of Toxicology. 2005 Dec; 88(2):551-61. doi: 10.1093/toxsci/kfi305. [PMID: 16141437]
  • J A Paniagua, J López-Miranda, P Pérez-Martínez, C Marín, J M Vida, F Fuentes, R A Fernández de la Puebla, F Pérez-Jiménez. Oxidized-LDL levels are changed during short-term serum glucose variations and lowered with statin treatment in early Type 2 diabetes: a study of endothelial function and microalbuminuria. Diabetic medicine : a journal of the British Diabetic Association. 2005 Dec; 22(12):1647-56. doi: 10.1111/j.1464-5491.2005.01703.x. [PMID: 16401307]
  • P G Fegan, A C Shore, D Mawson, J E Tooke, K M MacLeod. Microvascular endothelial function in subjects with Type 2 diabetes and the effect of lipid-lowering therapy. Diabetic medicine : a journal of the British Diabetic Association. 2005 Dec; 22(12):1670-6. doi: 10.1111/j.1464-5491.2005.01719.x. [PMID: 16401310]
  • Birgit Jaschke, Cornelia Michaelis, Stefan Milz, Michael Vogeser, Thomas Mund, Ludger Hengst, Adnan Kastrati, Albert Schömig, Rainer Wessely. Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. Cardiovascular research. 2005 Dec; 68(3):483-92. doi: 10.1016/j.cardiores.2005.06.029. [PMID: 16111664]
  • Timothy E Johnson, Xiaohua Zhang, Shu Shi, Diane R Umbenhauer. Statins and PPARalpha agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment. Toxicology and applied pharmacology. 2005 Nov; 208(3):210-21. doi: 10.1016/j.taap.2005.03.004. [PMID: 16239165]
  • J-M Corpataux, J Naik, K E Porter, N J M London. The effect of six different statins on the proliferation, migration, and invasion of human smooth muscle cells. The Journal of surgical research. 2005 Nov; 129(1):52-6. doi: 10.1016/j.jss.2005.05.016. [PMID: 16087194]
  • Soichiro Matsushima, Kazuya Maeda, Chihiro Kondo, Masaru Hirano, Makoto Sasaki, Hiroshi Suzuki, Yuichi Sugiyama. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. The Journal of pharmacology and experimental therapeutics. 2005 Sep; 314(3):1059-67. doi: 10.1124/jpet.105.085589. [PMID: 15901800]
  • Sevim Gullu, Rifat Emral, Mehmet Bastemir, Arthur B Parkes, John H Lazarus. In vivo and in vitro effects of statins on lymphocytes in patients with Hashimoto's thyroiditis. European journal of endocrinology. 2005 Jul; 153(1):41-8. doi: 10.1530/eje.1.01941. [PMID: 15994744]
  • Yoshio Kameyama, Keiko Yamashita, Kaoru Kobayashi, Masakiyo Hosokawa, Kan Chiba. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenetics and genomics. 2005 Jul; 15(7):513-22. doi: 10.1097/01.fpc.0000170913.73780.5f. [PMID: 15970799]
  • Scott M Grundy. The issue of statin safety: where do we stand?. Circulation. 2005 Jun; 111(23):3016-9. doi: 10.1161/circulationaha.105.557652. [PMID: 15911705]
  • Alawi A Alsheikh-Ali, Marietta S Ambrose, Jeffrey T Kuvin, Richard H Karas. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation. 2005 Jun; 111(23):3051-7. doi: 10.1161/circulationaha.105.555482. [PMID: 15911706]
  • B M Balletshofer, S Goebbel, K Rittig, M Enderle, I Schmölzer, T C Wascher, A Ferenc Pap, T Westermeier, D Petzinna, S Matthaei, H U Häring. Intense cholesterol lowering therapy with a HMG-CoA reductase inhibitor does not improve nitric oxide dependent endothelial function in type-2-diabetes--a multicenter, randomised, double-blind, three-arm placebo-controlled clinical trial. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. 2005 Jun; 113(6):324-30. doi: 10.1055/s-2005-865642. [PMID: 15977099]
  • Paola Cafforio, Franco Dammacco, Angela Gernone, Franco Silvestris. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis. 2005 May; 26(5):883-91. doi: 10.1093/carcin/bgi036. [PMID: 15705602]
  • H Ozaki, C T Ishikawa, T Ishii, A Toyoda, T Murano, Y Miyashita, K Shirai. Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis. Journal of clinical pharmacy and therapeutics. 2005 Apr; 30(2):189-92. doi: 10.1111/j.1365-2710.2005.00633_1.x. [PMID: 15811174]
  • Stefan John, Markus P Schneider, Christian Delles, Johannes Jacobi, Roland E Schmieder. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. American heart journal. 2005 Mar; 149(3):473. doi: 10.1016/j.ahj.2004.06.027. [PMID: 15864218]
  • Axel Kuettner, Anne Pieper, Jürgen Koch, Franz Enzmann, Stephen Schroeder. Influence of coenzyme Q(10) and cerivastatin on the flow-mediated vasodilation of the brachial artery: results of the ENDOTACT study. International journal of cardiology. 2005 Feb; 98(3):413-9. doi: 10.1016/j.ijcard.2004.01.004. [PMID: 15708173]
  • Annie H Shinn, Sian M Carr-Lopez, James W Smith, Elizabeth A Elledge, Timothy J Smith. Effects of switching pravastatin to cerivastatin on C-reactive protein, butyrylcholinesterase, and lipids. Current medical research and opinion. 2005 Feb; 21(2):207-14. doi: 10.1185/030079904x25550. [PMID: 15801991]
  • Mitsuo Saito, Mutsuko Hirata-Koizumi, Shinji Miyake, Ryuichi Hasegawa. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States]. Kokuritsu Iyakuhin Shokuhin Eisei Kenkyujo hokoku = Bulletin of National Institute of Health Sciences. 2005; ?(123):41-5. doi: . [PMID: 16541751]
  • Yoshihisa Shitara, Masaru Hirano, Yasuhisa Adachi, Tomoo Itoh, Hitoshi Sato, Yuichi Sugiyama. In vitro and in vivo correlation of the inhibitory effect of cyclosporin A on the transporter-mediated hepatic uptake of cerivastatin in rats. Drug metabolism and disposition: the biological fate of chemicals. 2004 Dec; 32(12):1468-75. doi: 10.1124/dmd.32.12.. [PMID: 15550721]
  • Akane Kizu, Atsushi Shioi, Shuichi Jono, Hidenori Koyama, Yasuhisa Okuno, Yoshiki Nishizawa. Statins inhibit in vitro calcification of human vascular smooth muscle cells induced by inflammatory mediators. Journal of cellular biochemistry. 2004 Nov; 93(5):1011-9. doi: 10.1002/jcb.20207. [PMID: 15389884]
  • N V S Ramakrishna, M Koteshwara, K N Vishwottam, S Puran, S Manoj, M Santosh. Simple, sensitive and rapid LC-MS/MS method for the quantitation of cerivastatin in human plasma--application to pharmacokinetic studies. Journal of pharmaceutical and biomedical analysis. 2004 Nov; 36(3):505-15. doi: 10.1016/j.jpba.2004.06.022. [PMID: 15522524]
  • Stephen J Leslie, James C Spratt, Lynn Grieg, Teresa Attina, Martin A Denvir, David J Webb. The effect of cerivastatin therapy on vascular responses to endothelin antagonists in humans. Journal of cardiovascular pharmacology. 2004 Nov; 44 Suppl 1(?):S410-2. doi: 10.1097/01.fjc.0000166290.95195.8b. [PMID: 15838335]
  • Michael H Davidson. Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. Expert opinion on drug safety. 2004 Nov; 3(6):547-57. doi: 10.1517/14740338.3.6.547. [PMID: 15500414]
  • Miran Sebestjen, Irena Keber, Branka Zegura, Sasa Simcic, Mojca Bozic, Martine Migaud Fressart, Mojca Stegnar. Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors. Thrombosis and haemostasis. 2004 Nov; 92(5):1129-35. doi: 10.1160/th03-04-0250. [PMID: 15543343]
  • Yoshihisa Shitara, Masaru Hirano, Hitoshi Sato, Yuichi Sugiyama. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. The Journal of pharmacology and experimental therapeutics. 2004 Oct; 311(1):228-36. doi: 10.1124/jpet.104.068536. [PMID: 15194707]
  • Toshifumi Shimada, Yoshiaki Takeshita, Toyoaki Murohara, Ken-ichiro Sasaki, Kimiyasu Egami, Satoshi Shintani, Yosuke Katsuda, Hisao Ikeda, Yo-ichi Nabeshima, Tsutomu Imaizumi. Angiogenesis and vasculogenesis are impaired in the precocious-aging klotho mouse. Circulation. 2004 Aug; 110(9):1148-55. doi: 10.1161/01.cir.0000139854.74847.99. [PMID: 15302783]
  • Maurizio Cesari, Achille C Pessina. Combined antihypertensive and lipid-lowering treatment. Current hypertension reports. 2004 Aug; 6(4):300-6. doi: 10.1007/s11906-004-0025-5. [PMID: 15257865]
  • Tetsuya Nakamura, Yuichiro Saito, Yoshio Ohyama, Tsuyoshi Uchiyama, Hiroyuki Sumino, Masahiko Kurabayashi. Effect of cerivastatin on endothelial dysfunction and aortic CD36 expression in diabetic hyperlipidemic rats. Hypertension research : official journal of the Japanese Society of Hypertension. 2004 Aug; 27(8):589-98. doi: 10.1291/hypres.27.589. [PMID: 15492479]
  • Kari T Kivistö, Jörg Zukunft, Ute Hofmann, Mikko Niemi, Sabine Rekersbrink, Swetlana Schneider, Gerd Luippold, Matthias Schwab, Michel Eichelbaum, Martin F Fromm. Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice. Naunyn-Schmiedeberg's archives of pharmacology. 2004 Aug; 370(2):124-30. doi: 10.1007/s00210-004-0948-z. [PMID: 15322734]
  • Seigo Sugiyama, Kiyotaka Kugiyama, Masanori Aikawa, Shinichi Nakamura, Hisao Ogawa, Peter Libby. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arteriosclerosis, thrombosis, and vascular biology. 2004 Jul; 24(7):1309-14. doi: 10.1161/01.atv.0000131784.50633.4f. [PMID: 15142860]
  • Koichi Sakabe, Nobuo Fukuda, Katsunori Wakayama, Teru Nada, Hisanori Shinohara, Yoshiyuki Tamura. Time course differences for statin-induced pleiotropic effects in hypercholesterolemic patients. International journal of cardiology. 2004 Mar; 94(1):111-7. doi: 10.1016/j.ijcard.2003.08.001. [PMID: 14996484]
  • U Laufs, S Wassmann, S Schackmann, C Heeschen, M Böhm, G Nickenig. Beneficial effects of statins in patients with non-ischemic heart failure. Zeitschrift fur Kardiologie. 2004 Feb; 93(2):103-8. doi: 10.1007/s00392-004-1005-0. [PMID: 14963675]
  • Ryu Takata, Shinya Fukasawa, Takeshi Hara, Hitoshi Nakajima, Akira Yamashina, Noriko Yanase, Junichiro Mizuguchi. Cerivastatin-induced apoptosis of human aortic smooth muscle cells through partial inhibition of basal activation of extracellular signal-regulated kinases. Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology. 2004 Jan; 13(1):41-8. doi: 10.1016/s1054-8807(03)00104-2. [PMID: 14761784]
  • Aukje K Mantel-Teeuwisse, Olaf H Klungel, Toine C G Egberts, W M Monique Verschuren, Arijan J Porsius, Anthonius de Boer. Failure to continue lipid-lowering drug use following the withdrawal of cerivastatin. Drug safety. 2004; 27(1):63-70. doi: 10.2165/00002018-200427010-00004. [PMID: 14720086]
  • Jayne E Edwards, R Andrew Moore. Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials. BMC family practice. 2003 Dec; 4(?):18. doi: 10.1186/1471-2296-4-18. [PMID: 14969594]
  • Rie Hakamada-Taguchi, Yoshio Uehara, Kagemasa Kuribayashi, Atsushi Numabe, Kanako Saito, Hideyuki Negoro, Toshiro Fujita, Teruhiko Toyo-oka, Takuma Kato. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circulation research. 2003 Nov; 93(10):948-56. doi: 10.1161/01.res.0000101298.76864.14. [PMID: 14563711]
  • L Renders, D Czock, H Schöcklmann, U Kunzendorf. Determination of the pharmacokinetics of cerivastatin when administered in combination with sirolimus and cyclosporin A in patients with kidney transplant, and review of the relevant literature. International journal of clinical pharmacology and therapeutics. 2003 Nov; 41(11):499-503. doi: 10.5414/cpp41499. [PMID: 14620947]
  • Christiane Viedt, Weili Shen, Jianwei Fei, Motohiro Kamimura, Gertrud M Hänsch, Hugo A Katus, Jörg Kreuzer. HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9. Basic research in cardiology. 2003 Nov; 98(6):353-61. doi: 10.1007/s00395-003-0437-4. [PMID: 14556080]
  • Daisuke Sugiyama, Hiroyuki Kusuhara, Hirokazu Taniguchi, Shumpei Ishikawa, Yoshitane Nozaki, Hiroyuki Aburatani, Yuichi Sugiyama. Functional characterization of rat brain-specific organic anion transporter (Oatp14) at the blood-brain barrier: high affinity transporter for thyroxine. The Journal of biological chemistry. 2003 Oct; 278(44):43489-95. doi: 10.1074/jbc.m306933200. [PMID: 12923172]
  • Koichi Shimizu, Masanori Aikawa, Kiyoshi Takayama, Peter Libby, Richard N Mitchell. Direct anti-inflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins. Circulation. 2003 Oct; 108(17):2113-20. doi: 10.1161/01.cir.0000092949.67153.74. [PMID: 14517172]
  • R P Brandes, S Beer, T Ha, R Busse. Withdrawal of cerivastatin induces monocyte chemoattractant protein 1 and tissue factor expression in cultured vascular smooth muscle cells. Arteriosclerosis, thrombosis, and vascular biology. 2003 Oct; 23(10):1794-800. doi: 10.1161/01.atv.0000092126.25380.bc. [PMID: 12933532]
  • Luca Puccetti, Anna Laura Pasqui, Marcello Pastorelli, Giovanni Bova, Michela Di Renzo, Alessandro Leo, Michela Cercignani, Alberto Palazzuoli, Alberto Auteri, Fulvio Bruni. Platelet hyperactivity after statin treatment discontinuation. Thrombosis and haemostasis. 2003 Sep; 90(3):476-82. doi: 10.1160/th03-02-0111. [PMID: 12958617]
  • Bo-qing Zhu, Christopher Heeschen, Richard E Sievers, Joel S Karliner, William W Parmley, Stanton A Glantz, John P Cooke. Second hand smoke stimulates tumor angiogenesis and growth. Cancer cell. 2003 Sep; 4(3):191-6. doi: 10.1016/s1535-6108(03)00219-8. [PMID: 14522253]
  • Lutz Renders, Christian S Haas, Jan Liebelt, Martin Oberbarnscheidt, Harald O Schöcklmann, Ulrich Kunzendorf. Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients. British journal of clinical pharmacology. 2003 Aug; 56(2):214-9. doi: 10.1046/j.1365-2125.2003.01870.x. [PMID: 12895195]
  • V van Harmelen, T Skurk, K Röhrig, H Hauner. HMG-CoA reductase inhibitor cerivastatin inhibits interleukin-6 expression and secretion in human adipocytes. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2003 Aug; 35(8):466-70. doi: 10.1055/s-2003-41803. [PMID: 12953163]
  • Julia Kirchheiner, Dirk Kudlicz, Christian Meisel, Steffen Bauer, Ingolf Meineke, Ivar Roots, Jürgen Brockmöller. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clinical pharmacology and therapeutics. 2003 Aug; 74(2):186-94. doi: 10.1016/s0009-9236(03)00121-8. [PMID: 12891229]
  • Vadim Z Lankin, Alla K Tikhaze, Valery V Kukharchuk, Galina G Konovalova, Oleg I Pisarenko, Alexander I Kaminnyi, Konstantin B Shumaev, Yury N Belenkov. Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins. Molecular and cellular biochemistry. 2003 Jul; 249(1-2):129-40. doi: ". [PMID: 12956408]
  • T Ota, T Takamura, H Ando, E Nohara, H Yamashita, K Kobayashi. Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia. 2003 Jun; 46(6):843-51. doi: 10.1007/s00125-003-1099-3. [PMID: 12774163]
  • Terry A Jacobson. Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era. Expert opinion on drug safety. 2003 May; 2(3):269-86. doi: 10.1517/14740338.2.3.269. [PMID: 12904106]
  • Petr Ostadal, David Alan, Petr Hajek, David Horak, Jiri Vejvoda, Jiri Trefanec, Martin Mates, Jan Vojacek. The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction. Molecular and cellular biochemistry. 2003 Apr; 246(1-2):45-50. doi: . [PMID: 12841342]
  • Dorothea I Siegel-Axel, Heike Runge, Ludger Seipel, Reimer Riessen. Effects of cerivastatin on human arterial smooth muscle cell growth and extracellular matrix expression at varying glucose and low-density lipoprotein levels. Journal of cardiovascular pharmacology. 2003 Mar; 41(3):422-33. doi: 10.1097/00005344-200303000-00011. [PMID: 12605021]
  • Beate Fisslthaler, U Ruth Michaelis, Voahanginirina Randriamboavonjy, Rudi Busse, Ingrid Fleming. Cytochrome P450 epoxygenases and vascular tone: novel role for HMG-CoA reductase inhibitors in the regulation of CYP 2C expression. Biochimica et biophysica acta. 2003 Feb; 1619(3):332-9. doi: 10.1016/s0304-4165(02)00492-0. [PMID: 12573493]
  • Hitomi Usui, Kenichi Shikata, Mitsuhiro Matsuda, Shinichi Okada, Daisuke Ogawa, Tetsuji Yamashita, Kazuyuki Hida, Minoru Satoh, Jun Wada, Hirofumi Makino. HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2003 Feb; 18(2):265-72. doi: 10.1093/ndt/18.2.265. [PMID: 12543879]
  • Yoshihisa Shitara, Tomoo Itoh, Hitoshi Sato, Albert P Li, Yuichi Sugiyama. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. The Journal of pharmacology and experimental therapeutics. 2003 Feb; 304(2):610-6. doi: 10.1124/jpet.102.041921. [PMID: 12538813]
  • Noako Yokota, Michael O'Donnell, Frank Daniels, Melissa Burne-Taney, William Keane, Bertram Kasiske, Hamid Rabb. Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury. American journal of nephrology. 2003 Jan; 23(1):13-7. doi: 10.1159/000066301. [PMID: 12373076]
  • T Ohno, M Shigetomi, K Ihara, K Ikeda, T Tsubone, T Matsunaga, T Sugiyama, S Kawai. Effects of cerivastatin on vascularized allogenic bone transplantation in rats treated with cyclosporine A. Calcified tissue international. 2003 Jan; 72(1):50-6. doi: 10.1007/s00223-002-2029-y. [PMID: 12384812]
  • Mira Choi, Susanne Rolle, Madhavi Rane, Hermann Haller, Friedrich C Luft, Ralph Kettritz. Extracellular signal-regulated kinase inhibition by statins inhibits neutrophil activation by ANCA. Kidney international. 2003 Jan; 63(1):96-106. doi: 10.1046/j.1523-1755.2003.00718.x. [PMID: 12472772]
  • D I Siegel-Axel. Cerivastatin: a cellular and molecular drug for the future?. Cellular and molecular life sciences : CMLS. 2003 Jan; 60(1):144-64. doi: 10.1007/s000180300010. [PMID: 12613664]
  • Yasamin Majlesi, Puchit Samorapoompichit, Alexander W Hauswirth, Gerit-Holger Schernthaner, Minoo Ghannadan, Mehrdad Baghestanian, Abdolreza Rezaie-Majd, Rudolf Valenta, Wolfgang R Sperr, Hans-Jörg Bühring, Peter Valent. Cerivastatin and atorvastatin inhibit IL-3-dependent differentiation and IgE-mediated histamine release in human basophils and downmodulate expression of the basophil-activation antigen CD203c/E-NPP3. Journal of leukocyte biology. 2003 Jan; 73(1):107-17. doi: 10.1189/jlb.0202075. [PMID: 12525568]
  • Seinosuke Kawashima, Tomoya Yamashita, Yoichi Miwa, Masanori Ozaki, Masayuki Namiki, Tetsuaki Hirase, Nobutaka Inoue, Ken-ichi Hirata, Mitsuhiro Yokoyama. HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats. Stroke. 2003 Jan; 34(1):157-63. doi: 10.1161/01.str.0000048213.18751.52. [PMID: 12511768]
  • Hideki Fujino, Iwao Yamada, Shimada Shimada, Masaru Hirano, Yoshihiko Tsunenari, Junji Kojima. Interaction between fibrates and statins--metabolic interactions with gemfibrozil. Drug metabolism and drug interactions. 2003; 19(3):161-76. doi: 10.1515/dmdi.2003.19.3.161. [PMID: 14682608]
  • Markus Zeitlinger, Markus Müller. [Clinico-pharmacologic explanation models of cerivastatin associated rhabdomyolysis]. Wiener medizinische Wochenschrift (1946). 2003; 153(11-12):250-4. doi: 10.1046/j.1563-258x.2003.03029.x. [PMID: 12879633]
  • Uwe Schönbeck, Norbert Gerdes, Nerea Varo, Rebecca S Reynolds, Daniel B Horton, Udo Bavendiek, Linda Robbie, Peter Ganz, Scott Kinlay, Peter Libby. Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation. 2002 Dec; 106(23):2888-93. doi: 10.1161/01.cir.0000043029.52803.7b. [PMID: 12460867]
  • L Kalinowski, I T Dobrucki, T Malinski. Cerivastatin potentiates nitric oxide release and enos expression through inhibition of isoprenoids synthesis. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2002 Dec; 53(4 Pt 1):585-95. doi: . [PMID: 12512694]
  • Janne T Backman, Carl Kyrklund, Mikko Neuvonen, Pertti J Neuvonen. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clinical pharmacology and therapeutics. 2002 Dec; 72(6):685-91. doi: 10.1067/mcp.2002.128469. [PMID: 12496749]
  • Gordon D Schiff, Leah M Keehr, Theophilus T Sai, Judilynn Bult. High rates of adverse effects and patient unawareness of withdrawn lipid-lowering drug combination in a public hospital clinic. Pharmacoepidemiology and drug safety. 2002 Dec; 11(8):643-5. doi: 10.1002/pds.778. [PMID: 12512238]
  • Rebecca A Viola, Kevin C Abbott, Paul G Welch, Robichaud J McMillan, Aatif M Sheikh, Christina M Yuan. A multidisciplinary program for achieving lipid goals in chronic hemodialysis patients. BMC nephrology. 2002 Nov; 3(?):9. doi: 10.1186/1471-2369-3-9. [PMID: 12431277]
  • John J Lewin, Jean M Nappi, Marian H Taylor. Rhabdomyolysis with concurrent atorvastatin and diltiazem. The Annals of pharmacotherapy. 2002 Oct; 36(10):1546-9. doi: 10.1345/aph.1a481. [PMID: 12243603]
  • Stefanie Zeuke, Artur J Ulmer, Shoichi Kusumoto, Hugo A Katus, Holger Heine. TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS. Cardiovascular research. 2002 Oct; 56(1):126-34. doi: 10.1016/s0008-6363(02)00512-6. [PMID: 12237173]